Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TRHR | P34981 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | PPM1B | O75688 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168269 | 0.83 | LTA4H (0.47) | CYP3A4ALDH1A1 | |
| SCHEMBL21168268 | 0.83 | LTA4H (0.47) | CYP3A4ALDH1A1 | |
| SCHEMBL21168333 | 0.81 | REN (0.45) | DPP4TRHRDPP7RENACE2 | |
| SCHEMBL21168281 | 0.81 | REN (0.45) | DPP4TRHRDPP7RENACE2 | |
| SCHEMBL18078245 | 0.80 | REN (0.39) | RENCYP3A4ACE2 | |
| SCHEMBL24058760 | 0.80 | REN (0.39) | RENCYP3A4ACE2 | |
| SCHEMBL21168328 | 0.80 | ACE (0.43) | DPP4DPP7RENCYP3A4ALDH1A1 | |
| SCHEMBL21168279 | 0.80 | ACE (0.43) | DPP4DPP7RENCYP3A4ALDH1A1 | |
| SCHEMBL21168332 | 0.79 | ACE (0.35) | RENCYP3A4ALDH1A1 | |
| SCHEMBL21168276 | 0.79 | ACE (0.35) | RENCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | CD47, CD63, CD99 | DPP4 4616/4885TRHR 2783/4885DPP7 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.